Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that new data supporting the potential of Atrioventricular Interval Modulation (AVIM) Therapy in managing hypertensive heart disease, which was …
Orchestra BioMed to Highlight AVIM Therapy’s Potential to Transform Hypertension Care Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) released new data at the HRX Live 2025 Meeting in Atlanta showing that its atrioventricular interval modulation (AVIM) therapy produces …
Orchestra BioMed Reports Long-Term Data Supporting AVIM Therapy for Hypertension Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced new data published in JACC: Clinical Electrophysiology demonstrating the potential of its atrioventricular interval modulation (AVIM) therapy to reduce …
Orchestra BioMed Publishes Data Supporting Blood Pressure Therapy in Hypertensive Pacemaker Patients Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has reported new clinical evidence suggesting its atrioventricular interval modulation (AVIM) therapy may significantly improve heart function in patients with …
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported second-quarter 2025 results alongside a series of major financing and regulatory developments that position the company to advance its …
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced a major expansion to the patient eligibility criteria for its ongoing BACKBEAT study, aimed at evaluating the effectiveness of its …
FDA Greenlights Broader Patient Access for AVIM Therapy Trial in Pacemaker Patients Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced $70 million in new capital commitments from Ligand Pharmaceuticals (Nasdaq: LGND) and Medtronic (NYSE: MDT), bolstering its efforts to …
Orchestra BioMed Secures $70 Million in Strategic Investments to Advance Cardiology Pipeline Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has presented key clinical insights into its atrioventricular interval modulation (AVIM) therapy for high-risk hypertension during the Congenital, Structural, and …
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its financial results for the first quarter ended March 31, 2025, alongside significant regulatory and clinical milestones that …
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced significant advancements in the intellectual property backing its AVIM (Atrioventricular Interval Modulation) therapy pipeline. Over the past year, …
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation Read More